These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34878777)

  • 1. Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II.
    Leenders RGG; Brinch SA; Sowa ST; Amundsen-Isaksen E; Galera-Prat A; Murthy S; Aertssen S; Smits JN; Nieczypor P; Damen E; Wegert A; Nazaré M; Lehtiö L; Waaler J; Krauss S
    J Med Chem; 2021 Dec; 64(24):17936-17949. PubMed ID: 34878777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor.
    Waaler J; Leenders RGG; Sowa ST; Alam Brinch S; Lycke M; Nieczypor P; Aertssen S; Murthy S; Galera-Prat A; Damen E; Wegert A; Nazaré M; Lehtiö L; Krauss S
    J Med Chem; 2020 Jul; 63(13):6834-6846. PubMed ID: 32511917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
    Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
    Voronkov A; Holsworth DD; Waaler J; Wilson SR; Ekblad B; Perdreau-Dahl H; Dinh H; Drewes G; Hopf C; Morth JP; Krauss S
    J Med Chem; 2013 Apr; 56(7):3012-23. PubMed ID: 23473363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
    Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
    Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.
    Waaler J; Machon O; Tumova L; Dinh H; Korinek V; Wilson SR; Paulsen JE; Pedersen NM; Eide TJ; Machonova O; Gradl D; Voronkov A; von Kries JP; Krauss S
    Cancer Res; 2012 Jun; 72(11):2822-32. PubMed ID: 22440753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Tankyrase Inhibitor OM-153 Demonstrates Antitumor Efficacy and a Therapeutic Window in Mouse Models.
    Brinch SA; Amundsen-Isaksen E; Espada S; Hammarström C; Aizenshtadt A; Olsen PA; Holmen L; Høyem M; Scholz H; Grødeland G; Sowa ST; Galera-Prat A; Lehtiö L; Meerts IATM; Leenders RGG; Wegert A; Krauss S; Waaler J
    Cancer Res Commun; 2022 Apr; 2(4):233-245. PubMed ID: 36873622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
    Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H
    Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H
    Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L; Wang X; Jia T; Wei W; Chua MS; So S
    Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
    Shirai F; Tsumura T; Yashiroda Y; Yuki H; Niwa H; Sato S; Chikada T; Koda Y; Washizuka K; Yoshimoto N; Abe M; Onuki T; Mazaki Y; Hirama C; Fukami T; Watanabe H; Honma T; Umehara T; Shirouzu M; Okue M; Kano Y; Watanabe T; Kitamura K; Shitara E; Muramatsu Y; Yoshida H; Mizutani A; Seimiya H; Yoshida M; Koyama H
    J Med Chem; 2019 Apr; 62(7):3407-3427. PubMed ID: 30883102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure, Dynamics, and Functionality of Tankyrase Inhibitor-Induced Degradasomes.
    Thorvaldsen TE; Pedersen NM; Wenzel EM; Schultz SW; Brech A; Liestøl K; Waaler J; Krauss S; Stenmark H
    Mol Cancer Res; 2015 Nov; 13(11):1487-501. PubMed ID: 26124443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
    Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
    J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.
    Nkizinkiko Y; Suneel Kumar BVS; Jeankumar VU; Haikarainen T; Koivunen J; Madhuri C; Yogeeswari P; Venkannagari H; Obaji E; Pihlajaniemi T; Sriram D; Lehtiö L
    Bioorg Med Chem; 2015 Aug; 23(15):4139-4149. PubMed ID: 26183543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase.
    Jang MK; Mashima T; Seimiya H
    Mol Cancer Ther; 2020 Mar; 19(3):765-776. PubMed ID: 31907221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Novel Inhibitor for WNT/β-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening.
    Li B; Liang J; Lu F; Zeng G; Zhang J; Ma Y; Liu P; Wang Q; Zhou Q; Chen L
    Molecules; 2020 Apr; 25(7):. PubMed ID: 32268564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.
    Shultz MD; Kirby CA; Stams T; Chin DN; Blank J; Charlat O; Cheng H; Cheung A; Cong F; Feng Y; Fortin PD; Hood T; Tyagi V; Xu M; Zhang B; Shao W
    J Med Chem; 2012 Feb; 55(3):1127-36. PubMed ID: 22260203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.
    Mariotti L; Pollock K; Guettler S
    Br J Pharmacol; 2017 Dec; 174(24):4611-4636. PubMed ID: 28910490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-Specific Regulation of the Wnt/β-Catenin Pathway by PAGE4 Inhibition of Tankyrase.
    Koirala S; Klein J; Zheng Y; Glenn NO; Eisemann T; Fon Tacer K; Miller DJ; Kulak O; Lu M; Finkelstein DB; Neale G; Tillman H; Vogel P; Strand DW; Lum L; Brautigam CA; Pascal JM; Clements WK; Potts PR
    Cell Rep; 2020 Jul; 32(3):107922. PubMed ID: 32698014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/β-catenin signaling pathway.
    Tian XH; Hou WJ; Fang Y; Fan J; Tong H; Bai SL; Chen Q; Xu H; Li Y
    J Exp Clin Cancer Res; 2013 Dec; 32(1):100. PubMed ID: 24308762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.